• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

    7/22/24 7:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANEB alert in real time by email

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"), to support the development of intravenous selonabant, for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression in children. The grant comes in the form of two tranches with the initial award of $0.9 million and subsequent funding of approximately $1 million subject to certain milestones. The grant was awarded under NIH award number 1U01DA059995-01.

    "We are honored to receive this cooperative grant award from NIDA to support the further development of intravenous selonabant," commented Ken Cundy, CSO of Anebulo Pharmaceuticals. "We believe this provides additional validation of the significant and growing unmet medical need for an emergency antidote to cannabis. Acute cannabis exposure in children represents a potentially life-threatening condition that can result in CNS depression, respiratory depression, coma, and in rare cases death. Research has shown that children are much more sensitive to the toxic effects of cannabis. Younger children have an underdeveloped endocannabinoid system with significantly more of the primary cannabinoid receptor type 1 (CB1) receptors present in their brains. As a direct consequence, pediatric cannabis ingestion can result in much more serious outcomes than in adults, and a much greater risk of hospitalization and admission to intensive care."

    "This important grant from NIDA recognizes the progress we have already made with the successful Phase 2 proof of concept study of oral selonabant and provides further momentum for advancing the intravenous formulation towards clinical testing," said Richie Cunningham, CEO, Anebulo Pharmaceuticals. "If approved, we believe selonabant has the potential to offer a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of accidental cannabis ingestion in children. This grant aligns with our recent decision to prioritize development of the intravenous formulation and we look forward to working closely with NIDA scientific staff on this important program."

    About Selonabant (ANEB-001)

    Our lead product candidate is selonabant (ANEB-001), a potent, small molecule antagonist of CB1, under development to address the unmet medical need for a specific antidote for cannabis toxicity, including ACI and unintentional cannabis poisoning. Selonabant is an orally bioavailable, readily absorbed treatment candidate that we anticipate will rapidly reverse key symptoms of ACI. Selonabant is also under development as a parenteral treatment for unintentional cannabis poisoning. Selonabant is protected by two issued patents covering various methods of use of the compound and composition of matter of the crystalline form of selonabant. We also have multiple pending applications covering various methods of use of the compound and delivery systems. An observational study in patients presenting to Emergency Departments with ACI is currently ongoing. The study will determine concentrations of cannabinoids and metabolites in plasma and gather information on signs and symptoms, patients' disposition and selected subjective assessments.

    About Anebulo Pharmaceuticals, Inc.

    Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication, unintentional cannabis intoxication and, longer term, for substance use disorders. Its lead product candidate, selonabant, has completed dosing in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. Selonabant is a competitive antagonist at the human CB1. For further information about Anebulo, please visit www.anebulo.com.

    Forward-Looking Statements

    Statements contained in this press release that are not statements of historical fact are forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by words such as "anticipate," "designed," "expect," "may," "will," "should" and other comparable terms. Forward-looking statements include statements regarding the potential use of selonabant as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression in children, the grant providing additional validation of the significant and growing unmet medical need for an emergency antidote to cannabis, acute cannabis exposure in children representing a potentially life-threatening condition that can result in CNS depression, respiratory depression, coma, and in rare cases death, children being much more sensitive to the toxic effects of cannabis, pediatric cannabis ingestion resulting in much more serious outcomes than in adults, and a much greater risk of hospitalization and admission to intensive care and working closely with the NIDA scientific staff and the potential of selonabant to offer a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of accidental cannabis ingestion in children . You are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to a number of risks, uncertainties and assumptions, including, but not limited to: our ability to pursue our regulatory strategy, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statements included in our Annual Report on Form 10-K for the year ended June 30, 2023, and our subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect new information, future events, changed conditions or otherwise after the date of this press release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240722151136/en/

    Get the next $ANEB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANEB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANEB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lawler Joseph F.

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    4/7/25 9:41:39 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Shah Bimal R.

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    4/7/25 9:41:38 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Cundy Kenneth C

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    4/7/25 9:41:37 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ANEB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

    Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three and twelve months ended June 30, 2025, and recent updates. Fourth Quarter Fiscal Year 2025 and Subsequent Highlights: On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will investigate the safety,

    9/29/25 4:05:00 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

    Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announces the first subjects dosed in its Phase 1 single ascending dose ("SAD") study of intravenous (IV) selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse (NIDA). First Subjects Dosed in Phase 1 SAD Study of Intravenous Selonabant Second year of NIDA collaborative grant ($994,300) awarded "This important milestone brings Anebulo closer to its goal of providing the first emergency antidote for ac

    9/25/25 7:30:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the "Company" or "Anebulo"), today announces an update on its current going private transaction. After announcing a going private transaction on July 23, 2025, the Company received inbound interest from potential financial and strategic partners. Consistent with our commitment to maximize stockholder value, the Board will review all strategic alternatives available to the Company, including the proposed going private transaction and related reverse stock split, a sale of the Company's assets and/or a merger trans

    9/12/25 7:30:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director English Aron R. bought $10,000,000 worth of shares (10,101,010 units at $0.99) (SEC Form 4)

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    12/26/24 4:15:08 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    SEC Filings

    View All

    SEC Form 10-K filed by Anebulo Pharmaceuticals Inc.

    10-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

    9/29/25 4:31:03 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

    9/29/25 4:15:30 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Anebulo Pharmaceuticals Inc.

    S-8 POS - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

    9/26/25 9:24:53 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Leadership Updates

    Live Leadership Updates

    View All

    Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve as a member of the board's audit and compensation committees. "I am pleased to welcome Bimal to the Anebulo Board," said Dr. Joseph Lawler, Anebulo's Chairman. "Bimal's depth of financial and business development experience in pharmaceutical companies will be valuable to Anebulo as we continue the development of ANEB-001." Mr. Shah is Chief Financial Officer of Corium LLC, a Boston-based commercial-stage bio

    10/6/23 4:06:00 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

    Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill AdvisorsSandra Gardiner succeeds Rex Merchant as acting chief financial officerAUSTIN, Texas, March 8, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) (the "Company" or "Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction, today announced the appointment of Sandra Gardiner as the Company's acting chief financial officer.  Ms. Gardiner joins Anebul

    3/8/23 8:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

    Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company" or "Anebulo"), today announced the appointment of Dr. Nat Calloway to its Board of Directors. Dr. Calloway will serve as a member of the Compensation Committee of the Board. "We are very pleased to welcome Nat to the Anebulo Board," said Simon Allen, Chief Executive Officer of Anebulo. "Nat's deep experience within the investment community and strong healthcare background will be invaluable to Anebulo as we continue the development of ANEB-001." Dr. Calloway is an analys

    11/1/22 4:00:00 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    Financials

    Live finance-specific insights

    View All

    Ligand Reports Third Quarter 2023 Financial Results

    Raising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We're pleased to report another quarter of strong financial results and we are now actively executing on our investment strategy as evidenced by the recent Tolerance, Ovid, Novan and Primrose transact

    11/8/23 4:01:00 PM ET
    $AMGN
    $ANEB
    $JAZZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ligand Reports First Quarter 2023 Financial Results

    2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

    5/4/23 4:01:00 PM ET
    $ANEB
    $LGND
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

    Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the "Company" or "Anebulo"), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of

    7/5/22 6:00:00 AM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care